If you have been diagnosed with localised prostate cancer, you may be wondering whether surgery can offer a meaningful benefit compared with monitoring your cancer. You may also have concerns about possible urinary or sexual side effects and whether treatment will improve your long-term health.
The Scandinavian Prostate Cancer Group Study Number 4, known as the SPCG-4 Trial, has helped doctors understand these important questions. It is one of the most influential long-term studies looking at radical prostatectomy for localised prostate cancer. Despite major advances in prostate cancer diagnosis and treatment, SPCG-4 remains one of the landmark randomised trials because of its exceptionally long follow-up, allowing researchers to understand outcomes that shorter studies cannot capture.
The trial showed that removing the prostate reduced prostate cancer deaths, distant metastases and the need for later treatment compared with watchful waiting. However, the benefits developed over many years, and your treatment decision should consider your cancer risk, life expectancy and personal circumstances rather than assuming surgery is right for everyone.
What Was the SPCG-4 Trial?
The SPCG-4 trial, known as the Scandinavian Prostate Cancer Group Study Number 4, was designed to compare radical prostatectomy with watchful waiting in men diagnosed with localised prostate cancer. If you are reading about this study today, understanding how it was designed can help you see how its findings apply to modern treatment decisions.
Recruitment for the trial began in 1989 and included 695 men from Sweden, Finland and Iceland who were randomly assigned to either surgery or watchful waiting. Random allocation helped researchers create two similar groups, allowing them to assess whether differences in outcomes were linked to the treatment approach rather than other factors.
Most cancers in the study were detected through clinical assessment rather than routine PSA screening. This means the participants often had more noticeable disease than you might see today, where cancers are frequently found earlier through PSA testing, MRI scans and targeted biopsies.
Why Was the Trial Needed?
Radical prostatectomy became more widely used as a potentially curative treatment during the late 1980s, but doctors still needed stronger evidence about whether it could help people live longer. If you are considering surgery, it is important to understand that the key question was not only whether the operation removed cancer, but whether it improved long-term outcomes for you.
Prostate cancer can behave very differently from one person to another. Some cancers may grow and spread, while others may remain within the prostate for many years without causing problems, which is why your individual cancer risk is so important.
SPCG-4 was created to answer these uncertainties by comparing immediate surgery with watchful waiting. The study looked at outcomes that matter to you, including survival, cancer spread, the need for further treatment, side effects and quality of life, with long-term follow-up helping researchers understand the true impact of each approach.
Evidence Note
SPCG-4 is regarded as one of the landmark randomised trials evaluating radical prostatectomy for localised prostate cancer. Its exceptionally long follow-up has provided valuable evidence on the long-term benefits and limitations of surgery, although modern diagnosis and treatment have evolved since the trial began.
How Did the Two Treatment Approaches Differ?
If you are diagnosed with localised prostate cancer, radical prostatectomy is one treatment option that aims to remove the cancer and provide long-term disease control. In the SPCG-4 trial, participants who received surgery underwent an operation designed to remove the prostate and surrounding tissues.
A radical prostatectomy involves removing your prostate gland and seminal vesicles, and nearby lymph nodes may also be removed depending on your cancer features and treatment plan. The surgery used in SPCG-4 reflected the techniques available at the time, so your experience with modern robot-assisted surgery may be different.
If you choose a watchful-waiting approach, your cancer is monitored rather than treated immediately with the aim of cure. Treatment such as hormone therapy or other supportive care may be offered later if your cancer progresses or starts causing symptoms.
What Were the Main Findings?
The main finding from SPCG-4 was that radical prostatectomy reduced the risk of dying from prostate cancer compared with watchful waiting. If you are considering treatment options, these results show that surgery can provide a long-term benefit for some people with localised prostate cancer.
The trial also found that surgery reduced the risk of distant metastases, meaning fewer people developed cancer that had spread to areas such as the bones or other organs. The benefits became clearer with longer follow-up, helping you understand why treatment outcomes may take many years to fully emerge.
After up to 29 years of follow-up, surgery was associated with lower prostate cancer mortality, fewer cases of cancer spread and improved overall survival. However, your decision should consider factors such as your cancer risk, life expectancy, general health and personal priorities.
How Did the Results Change Over Time?
One of the important lessons from SPCG-4 is that the impact of prostate cancer treatment may not be clear after only five or ten years. For you, this means long-term follow-up is essential because the benefits of treatment can take time to become visible.
The difference in prostate cancer mortality was initially modest but became larger as more participants were followed over a longer period. A later long-term analysis extending the SPCG-4 data estimated outcomes over approximately 30 years, with prostate cancer mortality estimated at 25.9% after radical prostatectomy compared with 42.9% with watchful waiting.
This resulted in an estimated absolute risk reduction of 17 percentage points at 30 years. The number of people needing surgery to prevent one prostate cancer death also decreased over time, from around 58 at five years to approximately six at 30 years, showing why your expected lifetime and cancer risk are important when considering treatment.
| Outcome | Radical prostatectomy | Watchful waiting | Approximate difference |
| Prostate cancer death at 23 years | 19.6% | 31.3% | 11.7 percentage points lower |
| Distant metastases at 23 years | 26.6% | 43.3% | 16.7 percentage points lower |
| Death from any cause at 23 years | 71.9% | 83.8% | 11.9 percentage points lower |
| Estimated prostate cancer death at 30 years | 25.9% | 42.9% | 17 percentage points lower |
| Estimated average life expectancy gained | Approximately 2.9 years | Reference group | Approximately 2.9 years |
These figures describe outcomes across the trial population. They cannot tell you exactly how much benefit you personally would receive from surgery.
Your possible benefit depends on the biological features of your cancer, your age, your health, your life expectancy and the likelihood that the cancer would progress without immediate treatment.
Why Is Absolute Risk So Important?
Relative risk figures can sometimes make the effect of a treatment appear larger or smaller depending on how they are presented. When you are considering treatment options, it is often more helpful to look at both the relative reduction and the actual difference in outcomes between the groups.
In the 23-year follow-up, an absolute difference of 11.7 percentage points in prostate cancer mortality meant that around 12 fewer deaths occurred per 100 people assigned to surgery compared with watchful waiting. This represents a meaningful benefit, but it also shows that not everyone would have needed surgery to avoid a prostate cancer death.
For you, the key point is that surgery is most likely to provide value when there is a realistic chance that the cancer could become harmful during your lifetime. Careful selection helps balance the potential benefits of treatment with the risks and side effects you may experience.
What Did SPCG-4 Show About Metastatic Disease?
Preventing prostate cancer deaths was not the only important finding from SPCG-4. The trial also showed that surgery reduced the risk of cancer spreading to distant parts of the body, which can have a major impact on your long-term health.
Metastatic prostate cancer often requires ongoing treatments and may lead to problems such as bone pain, fractures, urinary complications and fatigue. At 23 years, the estimated risk of distant metastases was lower after radical prostatectomy compared with watchful waiting.
For you, avoiding cancer spread may be an important benefit even before a clear survival advantage appears. Reducing the risk of metastatic disease may also help limit the need for long-term hormone treatment and other therapies used for advanced cancer.
Did Surgery Reduce the Need for Later Treatment?
Yes. In the SPCG-4 trial, people managed with watchful waiting were more likely to need hormone treatment and other palliative care as their cancer progressed. Surgery reduced the chance of needing these later treatments for some people.
However, the benefits were not the same for everyone. Some people in the watchful-waiting group never required palliative treatment, even after many years of follow-up, showing that immediate surgery may not always be necessary for every person.
The key message for you is that treatment decisions should be based on your individual cancer risk rather than treating every localised prostate cancer in the same way. Surgery can prevent progression for selected people, but avoiding immediate treatment may also be appropriate in certain situations.
Who Appeared to Benefit Most from Surgery?
The benefits of surgery were not the same for everyone in the SPCG-4 trial. The greatest advantage appeared to be among people who were younger than 65 when they entered the study, as they generally had more years in which untreated cancer could progress.
The study also suggested that people with intermediate-risk prostate cancer may have gained more benefit from surgery than those with very low-risk or very aggressive disease. For you, this highlights why your cancer risk group is an important factor when discussing treatment options.
Low-risk cancers may never become life-threatening, while very aggressive cancers may already have spread beyond the prostate. Intermediate-risk cancer can represent a situation where surgery may offer a meaningful chance of long-term control, as the disease has potential to progress but may still be curable with local treatment.
What Did the Trial Show About Surgical Side Effects?
The benefits of surgery need to be considered alongside its possible effects on your quality of life. Radical prostatectomy can affect urinary control and sexual function, so understanding these risks is an important part of your treatment decision.
After surgery, some people experience urinary leakage because the prostate plays a role in the urinary control system. Erectile function can also be affected, depending on factors such as your age, function before treatment, cancer location and whether nerve-sparing surgery is suitable for you.
Long-term SPCG-4 findings showed higher rates of urinary incontinence and erectile dysfunction after surgery compared with watchful waiting. However, watchful waiting also has disadvantages, as some people may develop urinary problems or need hormone treatment if the cancer progresses.
Hormone treatment can affect areas such as energy levels, sexual function, muscle strength, bone health, mood and metabolism. Your specialist will help you weigh these different outcomes, as quality of life can be affected in different ways depending on the treatment approach you choose.
| Possible consequence | Radical prostatectomy | Watchful waiting |
| Urinary leakage | More common after surgery | Less common initially |
| Erectile dysfunction | More common after surgery | May develop through ageing, disease progression or hormone treatment |
| Urinary obstruction | Usually relieved by removal of the prostate | May develop if the cancer or prostate grows locally |
| Need for hormone treatment | Less common during follow-up | More common if the cancer progresses |
| Risk of metastases | Lower in the trial | Higher in the trial |
| Recovery from a major operation | Required | Avoided unless another procedure became necessary |
The correct treatment decision depends partly on how you value these different outcomes. Some people prioritise reducing the future risk of metastases, while others place greater weight on avoiding immediate treatment side effects.
Why Is Watchful Waiting Different from Active Surveillance?
Watchful waiting and active surveillance are different approaches used for managing localised prostate cancer. The main difference is that active surveillance aims to delay treatment while keeping the option of cure, whereas watchful waiting focuses on managing symptoms if the cancer progresses.
- Watchful waiting is usually for people where curative treatment may offer limited benefit. This may be due to older age, other health conditions or personal preferences. Monitoring is generally less intensive, and treatment is started mainly to control symptoms.
- Active surveillance involves closer monitoring. It is used when the cancer appears low risk but could still be treated with curative intent if it shows signs of progression.
- Active surveillance may include regular checks and investigations. These can involve PSA tests, MRI scans, clinical reviews and repeat biopsies when needed to monitor changes in the cancer.
- Treatment may be recommended if the cancer changes. If there is clear evidence of progression, radical treatment such as surgery or radiotherapy may be considered.
Modern active surveillance means SPCG-4 results should not be interpreted as showing that surgery is always better. The trial did not compare surgery with today’s structured surveillance programmes designed to detect progression early.
What Were the Main Limitations of SPCG-4?
SPCG-4 provided strong evidence because it was a randomised trial with long-term follow-up lasting several decades. The study helped improve understanding of the benefits and risks of radical prostatectomy for localised prostate cancer.
However, no clinical trial can perfectly represent every person receiving treatment today. If you are considering surgery, it is important to understand how the study findings apply to your own cancer type, health and personal circumstances.
Modern diagnosis and treatment have changed significantly since SPCG-4 began. Your specialist will consider current evidence alongside your individual situation when discussing the most suitable approach for you.
Most cancers were clinically detected
Most cancers in the SPCG-4 trial were found through clinical assessment rather than widespread PSA screening. Only a small proportion of participants had cancers detected through PSA testing, and many had tumours that could already be felt or identified through other clinical signs.
Today, you may be diagnosed at an earlier stage because of PSA testing, MRI scans and targeted biopsies. These advances can identify smaller and lower-risk cancers that may not always need immediate treatment.
This means the people included in SPCG-4 are not exactly the same as everyone diagnosed with prostate cancer today. Your specialist will consider the type and risk level of your cancer when deciding whether surgery is likely to provide a meaningful benefit for you.
Watchful waiting was the comparison
The SPCG-4 trial compared surgery with watchful waiting, not with modern active surveillance. It also did not compare radical prostatectomy directly with contemporary radiotherapy, so the results do not provide a complete comparison of all treatments available to you today.
If you are considering your options, it is important to understand that modern alternatives have developed significantly since the trial was conducted. Active surveillance and radiotherapy now involve different approaches that were not fully represented in the original study.
You cannot use SPCG-4 alone to conclude that surgery is always better than these current treatments. Your specialist will consider your cancer risk, overall health and personal preferences when discussing which option may be most suitable for you.
Diagnostic methods have changed
Diagnostic methods have changed considerably since the SPCG-4 trial was conducted. Participants were assessed before tools such as multiparametric MRI, MRI-targeted biopsy and modern Grade Group classification became part of routine care.
Today, these advances can provide a clearer understanding of your cancer and help your specialist assess its risk more accurately. This means you may have more detailed information available when discussing whether treatment is needed.
Modern imaging and pathology can help distinguish cancers that are more likely to require treatment from those that may be safely monitored. For you, this supports a more personalised approach to deciding the right time and type of care.
Surgical techniques have changed
Surgical techniques have changed significantly since the SPCG-4 trial began. The study was conducted before robot-assisted surgery became widely used, and modern robotic approaches may offer benefits such as smaller incisions, less blood loss and a different early recovery experience for you.
However, the main principle of the operation remains the same: removing the prostate to treat cancer. If you are considering surgery today, your experience may differ from the outcomes reported in the original trial.
SPCG-4 provides important evidence about the cancer-control benefits of radical prostatectomy, but it should not be used as a direct estimate of every possible complication or recovery outcome at a modern specialist centre. Your surgeon will discuss the likely benefits, risks and expected recovery based on current techniques.
Supportive and additional treatments have improved
Supportive and additional treatments for prostate cancer have improved significantly since the SPCG-4 trial began. Advances in radiotherapy, hormone treatments, imaging and care for metastatic disease mean that your treatment options today may be different from those available during the original study period.
These developments can influence outcomes if your cancer returns or spreads after initial treatment. For you, this means modern care decisions need to consider both the evidence from older trials and the improvements available in current practice.
Your specialist will use the most up-to-date information alongside your individual situation when discussing treatment choices. This helps you understand the potential benefits and risks of each approach.
Subgroup results require caution
Subgroup results can help researchers identify possible patterns within a larger study, but they need to be interpreted carefully. Smaller groups within a trial often provide less reliable evidence than the overall findings.
Your treatment decision should not be based on a single factor, such as being slightly above or below the age of 65. Your cancer characteristics, overall health, life expectancy and personal preferences all play an important role.
When you discuss options with your specialist, they will consider the full picture rather than focusing on one individual feature. This helps ensure the recommended approach is suitable for you and your situation.
How Does SPCG-4 Influence Treatment Today?
The SPCG-4 trial showed that radical prostatectomy can provide benefits beyond lowering PSA levels or removing the visible tumour. For carefully selected people, surgery can reduce the risk of cancer spreading and lower the chance of dying from prostate cancer.
The findings have helped shape how prostate cancer treatment is approached today. If you are considering your options, the trial highlights the importance of choosing treatment based on your individual cancer risk rather than applying the same approach to everyone.
Its long-term influence can be seen in modern care, where factors such as your cancer characteristics, overall health, life expectancy and personal preferences are considered when planning treatment.
Clinically significant cancer may benefit from definitive local treatment
Clinically significant prostate cancer may benefit from treatment that aims to remove or control the cancer. If your cancer has a higher chance of progressing but is still potentially curable, radical treatment may improve your long-term outlook.
The SPCG-4 findings showed that surgery can provide important benefits for selected people with localised prostate cancer. However, the decision depends on factors such as your cancer features, overall health and personal circumstances.
When you discuss treatment options with your specialist, the aim is to understand whether the potential benefits of radical treatment are likely to outweigh the possible risks for you.
Benefits take time to emerge
The benefits of surgery may not become clear immediately. In the SPCG-4 study, the survival advantage of surgery became more noticeable after longer follow-up, showing why long-term outcomes are important when you consider treatment options.
For you, this means life expectancy is an important factor when deciding whether the possible benefits of surgery are likely to outweigh the risks. A treatment that provides benefits many years later may be more suitable for some people than others.
Your specialist will consider your age, overall health and cancer risk when discussing treatment. This helps you make a decision that balances potential cancer control with your quality of life.
Lower-risk cancer should not automatically be treated
Lower-risk prostate cancer does not always need immediate treatment. If you have suitable low-risk disease, active surveillance may allow you to monitor the cancer closely while avoiding or delaying treatment.
Many people in the watchful-waiting group never needed palliative treatment during the study period. Modern active surveillance has developed to help you safely manage certain low-risk cancers while reducing unnecessary treatment.
Your treatment choice should be based on your individual cancer features, overall health and personal preferences. This approach helps ensure you receive treatment when it is likely to provide a meaningful benefit for you.
Treatment decisions must include quality of life
Treatment decisions are not only about controlling cancer but also about protecting your quality of life. Surgery can reduce the risk of cancer progression, but it may also increase the chance of side effects that affect your daily life.
You should have a clear discussion about the possible benefits and risks before choosing treatment. Understanding how surgery may affect your urinary and sexual function can help you make a decision that feels right for your situation.
Your personal priorities, lifestyle and expectations are important parts of this conversation. The aim is to find a treatment approach that offers effective cancer control while considering what matters most to you.
Cancer risk matters more than the word “localised”
A cancer being described as “localised” does not always mean it carries the same level of risk. Two prostate cancers that are both limited to the prostate can behave very differently depending on their individual characteristics.
Your PSA level, Grade Group, clinical stage, MRI findings and biopsy results all help your specialist understand how your cancer may behave over time. These factors provide a clearer picture than the word “localised” alone.
When you are considering treatment options, these details can help determine whether surgery is likely to offer a worthwhile benefit for you. Your specialist will use this information alongside your overall health and personal priorities to guide the decision.
How Are Treatment Decisions Made in the UK?
In the UK, treatment decisions for localised prostate cancer are not based on one approach that suits everyone. Your recommended treatment will depend on factors such as your cancer risk group, overall health, life expectancy and personal preferences.
For lower-risk cancers, active surveillance may be recommended to monitor changes over time. If surveillance is not suitable or acceptable for you, treatments such as radical prostatectomy or radiotherapy may be considered depending on your individual situation.
For higher-risk localised disease, radical prostatectomy or radical radiotherapy may be offered when long-term cancer control is considered achievable. Your specialist will also consider whether active surveillance is appropriate based on your specific circumstances.
Your treatment discussion should include your PSA level, MRI findings, biopsy results, cancer stage, possible side effects and your own priorities. You should have the opportunity to understand the benefits and risks of each option so you can make an informed decision about your care.
What Did SPCG-4 Not Prove?
SPCG-4 did not prove that surgery is needed for everyone with prostate cancer. If you are considering treatment, it is important to understand that the study showed benefits for some men rather than one option that suits everyone.
The trial did not compare surgery with radiotherapy or modern active surveillance, so it cannot show that surgery is always better than these approaches. It also showed that surgery does not guarantee a cure, as some men still developed cancer progression after treatment.
The main message is that surgery can offer important long-term benefits for the right person. Your treatment decision should be based on several factors, including your cancer risk, overall health, life expectancy and personal preferences, so you can choose the approach that best fits your situation.
Myth vs Fact
| Myth | Fact |
| SPCG-4 proved everyone with prostate cancer should have surgery. | The study showed benefit only for selected men with localised disease. |
| Watchful waiting is the same as active surveillance. | They are different management strategies with different goals. |
| Surgery guarantees a cure. | Some men still experienced recurrence or progression. |
| Localised prostate cancer always needs treatment. | Many low-risk cancers can be safely monitored. |
| Robot-assisted surgery was used in SPCG-4. | The trial pre-dated modern robotic surgery. |
Key Takeaways:
- SPCG-4 showed radical prostatectomy reduced prostate cancer deaths compared with watchful waiting.
- The survival benefit became greater over long-term follow-up.
- Surgery also reduced distant metastases and the need for later hormone treatment.
- Modern diagnosis now includes PSA testing, MRI and targeted biopsy, which were not available during SPCG-4.
- Active surveillance differs from watchful waiting and is now appropriate for many men with low-risk prostate cancer.
- Treatment decisions should be based on cancer risk, life expectancy and personal preferences rather than the diagnosis of localised prostate cancer alone.
Frequently Asked Questions:
1. What was the main finding of the SPCG-4 Trial?
The SPCG-4 Trial found that radical prostatectomy reduced prostate cancer deaths, distant metastases and the need for later treatment compared with watchful waiting in men with localised prostate cancer. However, the benefit developed over many years and was greatest in people with a longer life expectancy and clinically significant disease.
2. Does the SPCG-4 Trial prove that everyone with prostate cancer needs surgery?
No. The trial showed that surgery can provide a survival benefit for selected patients, but it did not prove that every person with localised prostate cancer should have radical prostatectomy. Treatment decisions depend on cancer risk, age, overall health, life expectancy and personal preferences.
3. What is the difference between watchful waiting and active surveillance?
Watchful waiting involves monitoring cancer and starting treatment if symptoms or progression develop, usually with the aim of controlling the disease rather than curing it. Active surveillance is a more structured approach that uses PSA tests, MRI scans and biopsies to monitor suitable low-risk cancers while keeping curative treatment as an option.
4. Did the SPCG-4 Trial show that surgery improves survival?
Yes. Long-term follow-up showed that radical prostatectomy reduced prostate cancer mortality compared with watchful waiting. At around 23 years, the trial showed a lower risk of prostate cancer death and distant metastases among people who underwent surgery.
5. Who benefited most from surgery in the SPCG-4 Trial?
The greatest benefit appeared among younger participants and those with cancers more likely to progress, particularly some intermediate-risk cancers. However, age alone should not determine treatment, and decisions should consider overall health and life expectancy.
6. What are the risks of radical prostatectomy?
Radical prostatectomy can cause side effects including urinary leakage and erectile dysfunction. These risks need to be balanced against the potential benefit of reducing cancer progression and prostate cancer death.
7. Was the SPCG-4 Trial based on modern prostate cancer diagnosis?
No. Most participants were diagnosed before widespread PSA screening, MRI and targeted biopsy were available. Many had more clinically obvious cancers than those diagnosed today, so the results should be interpreted alongside modern diagnostic methods.
8. Did the SPCG-4 Trial compare surgery with radiotherapy?
No. The trial compared radical prostatectomy with watchful waiting only. It did not show whether surgery is better than modern radiotherapy or other treatment approaches.
9. Can someone with localised prostate cancer safely avoid surgery?
Some people can. Those with low-risk cancers may be suitable for active surveillance, while others with higher-risk cancers may benefit from surgery or radiotherapy. The decision depends on the characteristics of the cancer and the individual’s health circumstances.
10. How does the SPCG-4 Trial influence prostate cancer treatment today?
The trial helped establish that removing the prostate can improve long-term outcomes for appropriately selected patients. It also highlighted the importance of avoiding unnecessary treatment for cancers that may never cause harm, leading to today’s more personalised approach using risk assessment, MRI and active surveillance.
Final Thoughts: Understanding the Role of Surgery in Localised Prostate Cancer
The SPCG-4 Trial changed how doctors understand the potential benefits and limitations of surgery for localised prostate cancer. It showed that radical prostatectomy can reduce the risk of prostate cancer death and metastatic disease in selected patients, but it also highlighted that treatment decisions should be based on individual cancer characteristics, overall health and life expectancy.
Modern prostate cancer care has moved towards a more personalised approach, using tools such as MRI, risk assessment and active surveillance to identify who is most likely to benefit from treatment. Surgery can be an important option for some people, while others may be safely monitored depending on the nature of their cancer. If you are experiencing urinary symptoms or changes in PSA, you can contact us at Prostate Clinic London to arrange a consultation and discuss your concerns with a specialist.
References:
- Bill-Axelson, A., Holmberg, L., Garmo, H., et al. (2014) ‘Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer’, New England Journal of Medicine, 370(10), pp. 932–942. Available at: https://pubmed.ncbi.nlm.nih.gov/24597866/
- Bill-Axelson, A., Holmberg, L., Garmo, H., et al. (2018) ‘Radical Prostatectomy or Watchful Waiting in Prostate Cancer’, New England Journal of Medicine, 379, pp. 2319–2329. Available at: https://www.nejm.org/doi/10.1056/NEJMoa1807801
- Bill-Axelson, A., Holmberg, L., Ruutu, M., et al. (2011) ‘Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer’, New England Journal of Medicine, 364(18), pp. 1708–1717. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1011967
- National Institute for Health and Care Excellence (NICE) (2019, updated 2021) Prostate cancer: diagnosis and management (NG131). Available at: https://www.nice.org.uk/guidance/ng131
- European Association of Urology (EAU) (2025) EAU Guidelines on Prostate Cancer. Available at: https://uroweb.org/guidelines/prostate-cancer
- NHS (n.d.) Prostate cancer. Available at: https://www.nhs.uk/conditions/prostate-cancer/
- British Association of Urological Surgeons (BAUS) (n.d.) Prostate Cancer Information for Patients. Available at: https://www.baus.org.uk/patients/conditions/prostate_cancer/